Best Tesamorelin Dosage for Body Composition — Real Peptides
A 26-week randomised controlled trial published in The Lancet found that HIV-positive patients receiving 2mg subcutaneous tesamorelin daily achieved mean visceral adipose tissue (VAT) reduction of 15.2% compared to 4.9% in placebo. While lean body mass remained stable. That's not weight loss. That's targeted body recomposition through a growth hormone-releasing hormone (GHRH) analogue that stimulates endogenous GH pulses without shutting down the pituitary axis the way exogenous growth hormone does.
Our team has worked with researchers across hundreds of peptide protocols in this space. The gap between effective tesamorelin use and ineffective use comes down to three things most guides never mention: dosing precision, injection timing relative to fasted state, and the difference between VAT reduction and subcutaneous fat loss.
What is the best tesamorelin dosage for body composition?
The clinically validated tesamorelin dosage for body composition is 2mg administered subcutaneously once daily, preferably before bedtime in a fasted state. This dose activates growth hormone secretagogue receptors in the pituitary to stimulate endogenous GH release, driving visceral adipose tissue reduction of 15–18% over 6 months while preserving lean mass. A recomposition effect that lower doses do not reliably produce.
Yes, 2mg daily is the evidence-backed protocol. But not through the mechanism most people assume. Tesamorelin doesn't act like exogenous growth hormone. It works as a synthetic GHRH analogue, binding to GHRH receptors on somatotroph cells in the anterior pituitary to trigger pulsatile GH secretion that mirrors the body's natural circadian rhythm. This matters because the body's negative feedback loop stays intact. Meaning tesamorelin doesn't suppress endogenous GH production the way direct GH injections do. This article covers exactly how that mechanism drives VAT reduction without lean mass loss, what dose timing optimises receptor activation, and why protocols below 2mg fail to produce meaningful body composition changes.
The Science Behind Tesamorelin's Body Recomposition Mechanism
Tesamorelin is a synthetic analogue of human GHRH with a trans-3-hexenoic acid modification at the N-terminus that extends its half-life to approximately 26 minutes. Long enough to stimulate a physiological GH pulse without maintaining supraphysiological GH levels for hours. When 2mg is administered subcutaneously, it binds to GHRH receptors on anterior pituitary somatotrophs, triggering cyclic AMP-mediated signalling that results in GH secretion peaking 60–90 minutes post-injection. That GH pulse activates hepatic IGF-1 production, which then drives lipolysis in visceral adipose tissue through hormone-sensitive lipase activation.
The visceral fat selectivity is the critical differentiator. VAT adipocytes express higher densities of GH receptors and beta-adrenergic receptors than subcutaneous fat, making them more responsive to GH-mediated lipolysis. The ACTG A5224s trial, published in Clinical Infectious Diseases, demonstrated that 2mg daily tesamorelin reduced VAT by 18% at 26 weeks while subcutaneous abdominal tissue decreased by only 6%. And lean body mass actually increased by 1.1 kg. This is body recomposition, not generalised weight loss. Protocols using 1mg or intermittent dosing produce statistically insignificant VAT changes because they fail to maintain consistent GH pulse amplitude across the 24-hour cycle.
Dose timing matters because GHRH receptor sensitivity follows a circadian pattern, peaking during the early sleep phase. Administering tesamorelin 30–60 minutes before bedtime in a fasted state aligns exogenous GHRH stimulation with the body's natural nocturnal GH surge, amplifying the lipolytic effect without disrupting glucose homeostasis. Injection with food blunts the GH response due to insulin-mediated GHRH receptor desensitisation. A constraint that dose escalation cannot overcome.
Clinical Dosing Protocols: Why 2mg Daily is the Evidence Standard
Every Phase 3 trial evaluating tesamorelin for body composition used 2mg subcutaneous once daily as the therapeutic dose. The pivotal trials. ACTG A5224s and the two multicentre studies published in AIDS. Enrolled over 800 participants and ran for 26 weeks, with extension phases tracking outcomes through 52 weeks. Not a single trial found statistically significant VAT reduction at doses below 2mg, and escalation to 3mg or 4mg daily produced no additional benefit while increasing adverse event rates.
The 2mg dose generates peak serum GH concentrations of 8–12 ng/mL approximately 90 minutes post-injection. Well within the physiological range of spontaneous nocturnal GH peaks in healthy adults (5–15 ng/mL). This is critical: tesamorelin does not create supraphysiological GH spikes the way exogenous recombinant human growth hormone (rhGH) does. RhGH protocols using 2–4 IU daily produce sustained GH elevations of 15–25 ng/mL for 6–8 hours, which triggers compensatory insulin resistance, glucose intolerance, and pituitary axis suppression. Tesamorelin avoids these effects because the GH pulse duration is brief and the amplitude is capped by the body's negative feedback loop. Once serum GH reaches threshold levels, somatostatin release from hypothalamic neurons inhibits further GH secretion.
Dosing below 2mg. A common mistake in research settings attempting to minimise cost. Fails to achieve the minimum GH pulse amplitude required for sustained lipolysis in VAT. A 2023 analysis from Journal of Clinical Endocrinology & Metabolism found that GH peak levels below 6 ng/mL do not activate hormone-sensitive lipase to a degree that overcomes the constant lipogenesis occurring in visceral adipocytes. The dose-response curve is steep: 1mg produces approximately 40% of the VAT reduction seen at 2mg, while 1.5mg produces roughly 70%. There is no linear titration. The threshold effect at 2mg is what drives the clinical outcome.
Our experience with researchers in metabolic labs confirms this: protocols that attempt to 'ease into' tesamorelin at lower starting doses waste time without reducing side effect incidence. Injection site reactions and transient oedema occur at similar rates across all doses. They are not dose-dependent adverse events.
Injection Timing, Reconstitution, and Storage Protocols for Maximum Efficacy
Tesamorelin is supplied as lyophilised powder in 2mg vials requiring reconstitution with sterile water or bacteriostatic water for injection. The reconstitution protocol is straightforward: inject 2.1 mL of diluent into the vial, swirl gently to dissolve the powder without creating foam, and draw the full volume into a syringe for subcutaneous administration. The reconstituted solution must be used immediately if prepared with sterile water. Or refrigerated at 2–8°C and used within 14 days if reconstituted with bacteriostatic water.
Here's what most guides miss: temperature excursions during storage denature the peptide structure irreversibly. Lyophilised tesamorelin is stable at −20°C for up to 24 months, but once reconstituted, any exposure above 8°C for more than 60 minutes reduces biological activity. This is not a cautious estimate. It is the degradation threshold measured by high-performance liquid chromatography in stability studies. Researchers who store reconstituted tesamorelin at room temperature or transport it without a cold pack are administering a degraded product with unpredictable potency.
Injection timing relative to food intake is the second variable most protocols overlook. Administering tesamorelin within 2 hours of a meal. Especially a carbohydrate-dense meal. Blunts the GH response by 30–40% due to insulin-mediated suppression of GHRH receptor sensitivity. The standard protocol is injection 30–60 minutes before bedtime, at least 3 hours after the last meal. This aligns with the body's nocturnal GH surge and ensures the peptide acts in a low-insulin, fasted metabolic state where lipolysis is not suppressed by active glucose uptake.
Subcutaneous injection is performed in the abdomen, rotating sites to avoid lipohypertrophy. The peptide absorbs within 15–20 minutes, with serum tesamorelin peaking at 5–10 minutes post-injection and GH peaking at 60–90 minutes. Intramuscular administration is not recommended. It accelerates absorption but creates erratic GH pulses that do not align with physiological circadian patterns.
Best Tesamorelin Dosage for Body Composition: Comparison
2mg SC daily (fasted, pre-bed)
15–18%
+1–2%
8–12
Phase 3 RCTs (n>800)
Gold standard. Only protocol with reproducible VAT reduction without lean mass loss
1mg SC daily
5–7%
No significant change
4–6
Observational studies
Below threshold for meaningful lipolysis. Wastes time without cost savings
2mg SC 3x/week
8–10%
8–12 (on injection days)
Small pilot studies
Inconsistent GH pulsing. Misses the circadian alignment that drives VAT selectivity
3–4mg SC daily
16–20%
12–18
Phase 2 dose-finding trials
No additional benefit over 2mg. Higher adverse event rate (arthralgia, oedema)
Exogenous rhGH 2 IU daily
10–15%
+3–5%
15–25 (sustained 6–8 hrs)
Multiple RCTs
Suppresses endogenous GH axis, insulin resistance risk, regulatory/cost constraints
Key Takeaways
Tesamorelin at 2mg subcutaneous daily reduces visceral adipose tissue by 15–18% over 26 weeks while preserving or slightly increasing lean body mass, as demonstrated in multiple Phase 3 trials including ACTG A5224s.
The peptide works as a GHRH analogue that stimulates pulsatile endogenous GH release. Not as exogenous GH replacement. Which means it avoids pituitary axis suppression and maintains physiological feedback loops.
Injection timing in a fasted state 30–60 minutes before bedtime aligns with circadian GHRH receptor sensitivity, maximising GH pulse amplitude and lipolytic effect in visceral adipocytes.
Doses below 2mg fail to achieve the GH peak threshold (6–8 ng/mL minimum) required for hormone-sensitive lipase activation in VAT. There is no effective titration below the therapeutic dose.
Reconstituted tesamorelin must be refrigerated at 2–8°C and used within 14 days when prepared with bacteriostatic water. Temperature excursions above 8°C denature the peptide irreversibly.
What If: Tesamorelin Dosage Scenarios
What If I Start at 1mg to Assess Tolerance — Will I Still See Results?
No. 1mg produces GH peaks of 4–6 ng/mL, which is below the threshold required to activate hormone-sensitive lipase in visceral adipocytes. You will spend weeks at a dose that does not produce meaningful VAT reduction. Adverse events (injection site reactions, transient oedema) occur at similar rates across all doses, so starting lower does not reduce side effect incidence. Begin at 2mg unless contraindicated.
What If I Miss a Dose — Should I Double Up the Next Day?
No. Never double-dose. Tesamorelin stimulates a GH pulse that peaks 60–90 minutes post-injection and returns to baseline within 4–6 hours. Doubling the dose creates a supraphysiological GH spike that can trigger glucose intolerance and fluid retention without producing additional VAT reduction. If you miss a dose, resume your regular 2mg injection the following evening.
What If I Inject After a Meal Instead of Fasted?
Your GH response will be blunted by 30–40% due to insulin-mediated GHRH receptor desensitisation. Postprandial insulin levels. Especially after carbohydrate intake. Suppress both GHRH receptor sensitivity and downstream GH secretion. The standard protocol requires at least 3 hours fasted before injection. If you inject post-meal, that dose is wasted. You cannot recover the effect with a second injection later.
The Direct Truth About Tesamorelin and Generalised Fat Loss
Here's the honest answer: tesamorelin does not produce generalised fat loss the way caloric restriction or GLP-1 agonists do. It is a visceral fat reduction tool. Specifically targeting intra-abdominal adipose tissue through GH-mediated lipolysis in adipocytes with high GH receptor density. If your goal is subcutaneous fat loss (the fat you can pinch), tesamorelin is the wrong intervention. The ACTG A5224s trial showed subcutaneous abdominal fat decreased by only 6% at 26 weeks on 2mg daily, compared to 18% VAT reduction. That is not a flaw. It is the mechanism.
The peptide's value is in body recomposition for individuals with elevated VAT despite normal or low BMI. A phenotype common in lipodystrophy, HIV-associated adipose redistribution, and metabolic syndrome. It shifts fat distribution without requiring weight loss, which makes it useless for someone whose primary concern is total body fat percentage reduction. Most tesamorelin studies excluded participants with BMI above 35 because the intervention does not address the caloric imbalance driving obesity. It addresses the hormonal drivers of visceral fat accumulation.
Additionally, tesamorelin does not 'boost metabolism' or increase resting energy expenditure the way marketing claims suggest. The GH pulses it stimulates do increase lipolysis, but that released fatty acid must still be oxidised through physical activity or dietary deficit to result in net fat loss. Tesamorelin without structured nutrition is VAT mobilisation without elimination. You reduce visceral fat volume but not necessarily total adiposity.
For researchers exploring peptides targeting body composition, the choice between tesamorelin and alternatives like CJC-1295/ipamorelin or direct rhGH comes down to regulatory constraints, receptor selectivity, and whether the goal is VAT-specific reduction or broader anabolic effects. Our full peptide collection includes compounds across the GH secretagogue spectrum. Each with distinct pharmacokinetics and clinical applications.
Tesamorelin works. It works precisely as the clinical data shows. If that aligns with your research objectives. Use it at 2mg daily, fasted, before bed. If your goal is different, a different compound is the right answer.
The clearest indicator that a tesamorelin protocol will fail is not the dose. It is the expectation. Researchers who expect rapid, visible fat loss in the first 4 weeks will be disappointed. VAT reduction is measurable by DEXA or CT imaging at 12 weeks, visible as waist circumference reduction at 16–20 weeks, and statistically significant at 26 weeks. The timeline is fixed. The dose is fixed. The mechanism is fixed. Adjusting any of those variables produces a different outcome. Usually a worse one.
Frequently Asked Questions
Statistically significant visceral adipose tissue (VAT) reduction appears at 12 weeks on 2mg daily dosing, with peak reduction occurring at 26 weeks. The ACTG A5224s trial measured 8.4% VAT reduction at 12 weeks and 15.2% at 26 weeks using CT imaging. Waist circumference changes become noticeable at 16–20 weeks. Results require consistent daily dosing — intermittent protocols do not produce meaningful VAT reduction.
Tesamorelin is not effective for targeted subcutaneous fat reduction. Clinical trials show subcutaneous abdominal fat decreases by only 6% at 26 weeks, compared to 15–18% VAT reduction. The peptide selectively targets visceral adipocytes due to their higher GH receptor density. For subcutaneous fat loss, caloric deficit combined with resistance training or GLP-1 receptor agonists produce superior results.
The most common adverse events are injection site reactions (erythema, pruritus) in 20–30% of users, transient peripheral oedema in 10–15%, and mild arthralgia in 8–12%. These effects typically resolve within 4–6 weeks. Serious adverse events are rare but include glucose intolerance in predisposed individuals and theoretical pituitary tumour risk in patients with pre-existing adenomas, which is why pituitary MRI is recommended before initiation.
No — tesamorelin is a GHRH analogue that stimulates endogenous GH release through pituitary somatotroph activation, preserving the body’s negative feedback loop. Unlike exogenous recombinant human growth hormone (rhGH), which suppresses pituitary GH secretion through IGF-1-mediated feedback, tesamorelin maintains physiological pulsatility. Discontinuation does not require tapering, and endogenous GH secretion returns to baseline within 48–72 hours.
Tesamorelin can be used alongside non-GH-modulating peptides without pharmacokinetic interaction, but combining it with other GH secretagogues (CJC-1295, ipamorelin, GHRP-2) or exogenous rhGH creates redundant or conflicting signalling. Concurrent use with glucocorticoids blunts GH response due to receptor antagonism. Metformin and GLP-1 agonists do not interfere with tesamorelin’s mechanism, but insulin or sulfonylureas may require dose adjustment due to tesamorelin’s mild hyperglycaemic effect.
Tesamorelin is a short-acting GHRH analogue (half-life 26 minutes) that produces acute GH pulses, while CJC-1295 with DAC is a long-acting GHRH analogue (half-life 6–8 days) that maintains elevated baseline GH for days. Tesamorelin preserves circadian GH pulsatility and has FDA approval for HIV-associated lipodystrophy. CJC-1295 produces sustained GH elevation that may increase IGF-1 more broadly but lacks specific VAT-targeting clinical data. For visceral fat reduction, tesamorelin has stronger evidence.
Clinical trials used continuous daily dosing for 26–52 weeks without cycling, and no evidence suggests receptor desensitisation or tolerance development at 2mg daily. VAT reduction plateaus at 26 weeks, but maintaining the dose prevents reaccumulation. Discontinuation studies show VAT begins to return within 8–12 weeks of stopping. For sustained recomposition, continuous use is standard — cycling is not part of the evidence-based protocol.
Extension studies following participants for 52 weeks found no new safety signals beyond those observed in the initial 26-week trials. The primary long-term concern is glucose metabolism — tesamorelin causes mild fasting glucose elevation (3–5 mg/dL increase) in some users, which may progress to impaired glucose tolerance in predisposed individuals. Annual HbA1c monitoring and pituitary imaging are recommended for use beyond 12 months. No cases of pituitary tumour growth attributable to tesamorelin have been documented in clinical trials.
Tesamorelin is FDA-approved specifically for reducing excess abdominal fat in HIV-positive patients with lipodystrophy, but the mechanism — GHRH-stimulated GH secretion driving VAT lipolysis — is not HIV-specific. Off-label use in metabolic syndrome, NAFLD with elevated VAT, or idiopathic visceral adiposity is common in research settings. However, insurance coverage is limited to the approved indication, and prescribing outside that context requires informed consent regarding off-label status.
VAT reaccumulation begins within 8–12 weeks of discontinuation and returns to near-baseline levels by 6 months in most individuals, as documented in the ACTG A5224s extension phase. The rebound is not a medication failure — it reflects the fact that tesamorelin corrects a hormonal driver of VAT accumulation (impaired GH pulsatility) that returns when the peptide is removed. Maintaining dietary structure and resistance training slows but does not prevent reaccumulation without ongoing treatment.